TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Comprehensive income (loss) attributable to redeemable and non-redeemable non-controlling interests | - | 33 | 114 | -61 |
| Net income (loss) | 283 | 220 | -390 | -874 |
| Currency translation adjustment | 227 | 494 | 174 | -145 |
| Unrealized loss on defined benefit plans | - | -1 | -1 | - |
| Unrealized gain (loss) from derivative financial instruments, net | 17 | 7 | 7 | 7 |
| Total other comprehensive income (loss) | 244 | 500 | 180 | -138 |
| Total comprehensive income (loss) | 527 | 720 | -210 | -1,012 |
| Comprehensive income (loss) attributable to teva | 527 | 687 | -324 | -951 |
| Earnings per share, basic | 0.25 | 0.19 | -0.39 | -0.75 |
| Earnings per share, diluted | 0.24 | 0.18 | -0.39 | -0.75 |
| Weighted average number of shares outstanding, basic | 1,147,000,000 | 1,138,000,000 | 1,133,000,000 | 1,133,000,000 |
| Weighted average number of shares outstanding, diluted | 1,161,000,000 | 1,159,000,000 | 1,133,000,000 | 1,133,000,000 |